Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
View Older Stories View More Recent Stories
-
Form 8.3 - [DX (Group) plc - 09 11 2023] - (CGAML)
-
Canaccord Genuity Downgrades Illumina (ILMN) to Hold, 'near-term outlook appears soft '
-
PacBio to Present at Upcoming Investor Conferences
-
Form 8.3 - [UK Commercial Property REIT Limited 08 11 2023 - Opening Disclosure] - (CGWL)
-
Form 8.3 - [Picton Property Income Limited 08 11 2023 - Opening Disclosure] - (CGWL) - Correction for part 1F
-
Endologix to Present in Two Upcoming Healthcare Conferences
-
Biodesix to Participate in Two Upcoming Investor Conferences in November
-
Form 8.3 - [Picton Property Income Limited - Opening Disclosure - 08 11 2023] - (CGWL)
-
Artivion to Participate in Upcoming Investor Conferences
-
Total Gross Proceeds of $34,976,375 Raised
-
Castle Biosciences to Present at Upcoming Investor Conferences
-
Sponsors Announced for the 2024 ICR Conference
-
DocGo Announces Attendance at November 2023 Investor Conferences
-
Rapid Micro Biosystems to Participate in Upcoming Investor Conferences
-
Salarius Pharmaceuticals, Inc. (SLRX) Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program
-
Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program
-
electroCore to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum
-
Playmaker Capital Inc. Enters Into Definitive Agreement to Be Acquired by Better Collective
-
Clover Health Reports Third Quarter 2023 Results; Highlights Continued Improvement in Financial Performance and Improved 2023 Guidance
-
New Found Closes $56 Million Bought Deal Financing
-
Form 8.3 - [DX (GROUP) PLC - 03 11 2023] - (CGAML)
-
T2 Biosystems to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
-
Tombill Mines Announces Closing of Private Placement
-
Exagen Inc. to Participate in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
-
Exagen Inc. to Participate in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
-
Discovery 2023 Short Duration LP Raises The Maximum - $25 Million
-
Lucid Diagnostics to Present at Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum
-
Confluent crashes 33% on soft Q4 sales forecast; Triggers analyst downgrades
-
Akoya to Participate at Three Upcoming Investor Conferences
-
InspireMD to Participate in Upcoming November Investor Conferences
-
Peloton forecasts weak holiday-quarter revenue as demand slowdown bites
-
Qualcomm rallies on signs smartphone market slump is easing
-
Southern Energy Corp. Announces Results of Fundraising
-
Arrow Announces Blocklisting Update
-
MicroStrategy Announces Third Quarter 2023 Financial Results
-
DLP Resources Announces Closing of Second and Final Tranche of Over-Subscribed Private Placement of Units
-
Southern Energy Corp. Announces Proposed Equity Fundraising
-
Quantum-Si to Participate at Two Upcoming Investor Conferences
-
Electromed, Inc. to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
-
Nuwellis Announces Board of Directors Transition
-
SunOpta Inc. to Participate in Upcoming Investor Conferences
-
Form 8.3 - [Sopheon plc - Opening Declaration - 31 03 2023] - (CGAML)
-
Pulmonx to Participate at Upcoming Investor Conferences
-
Odey Asset Management to close - website statement
-
CANACCORD GENUITY GROUP INC. ACCESS TO SECOND QUARTER FISCAL 2024 RESULTS INFORMATION
-
Annovis Bio Inc. (ANVS) Prices 1.25M Share Offering at $6/sh
-
Annovis Bio Announces Pricing of $7.5 Million Public Offering
-
Final Results
-
Annovis Bio Inc. (ANVS) Announces Proposed Share Offering
-
Annovis Bio Announces Launch of Proposed Public Offering

